ht-0712 ht-0712 ht-0712, also known as ipl-455903, is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. it is currently being licensed by helicon therapeutics in san diego, california. it was originally discovered and tested as part of a preclinical anti-inflammatory program by inflazyme pharmaceuticals. ht-0712clinical dataother namesht-0712, ipl 455,903atc codenoneidentifiers iupac name (3s,5s)-5-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one cas number617720-02-2pubchem cid9865375chemspider8041067 yunii2o43fxg9igcomptox dashboard (epa)dtxsid70893926 chemical and physical dataformulac25h31no3molar mass393.527 g·mol−13d model (jsmol)interactive image smiles o=c3nc(c2cc(oc1cccc1)c(oc)cc2)c3cc4cccc(c4)c inchi inchi=1s/c25h31no3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22h,3-4,8-9,13-14,16h2,1-2h3,(h,26,27)/t20-,21-/m1/s1 ykey:abejdmobaflqnj-nhcuhlmssa-n y (verify) mechanism of action ht-0712 appears to act as a pde4 inhibitor, thereby increasing camp levels. when camp levels are increased in neurons, this may trigger activation of camp response element-binding proteins (creb). crebs are transcription factors involved in the formation of long-term memory. the side effects of the drug are not yet fully known. research a 2014 study found that ht-0712 significantly boosted memory formation in mice. data also indicated that ht-0712 may be effective to treat age-associated memory impairment in humans.